2021 Essex County Council election

Oncolytics Biotech® Announces Presentations at the Upcoming San Antonio Breast Cancer Symposium

Retrieved on: 
Monday, November 21, 2022
SAN, 2021 Essex County Council election, Cancer, TSX, Letrozole, Lymphatic system, PIK3CA, Survival, Neoplasm, Immunotherapy, Paclitaxel, Even and odd functions, Global Vision, EP4, Biotechnology, AB, Safety, Breast cancer, Progression-free survival, Roche, Travel, Phenotype, Research, Patient, COVID-19, ONC, Clinical trial, SD, PD-L1, Diagnosis, Regulation, Biomarker, Pancreatic cancer, Pharmaceutical industry, Medical imaging, Oncolytics Biotech, Pelareorep

(NASDAQ: ONCY) (TSX: ONC) today announced the publication of two abstracts for poster presentations at the upcoming San Antonio Breast Cancer Symposium (SABCS), to be held at the Henry B. Gonzlez Convention Center in San Antonio, Texas from December 6 10, 2022.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today announced the publication of two abstracts for poster presentations at the upcoming San Antonio Breast Cancer Symposium (SABCS), to be held at the Henry B. Gonzlez Convention Center in San Antonio, Texas from December 6 10, 2022.
  • Thebridging trial is designed to accelerate Adlai Nortye's development of pelareorep in China by allowingfuture regulatory submissions to include data from Oncolytics' North American metastatic breast cancer trials, IND-213 and BRACELET-1.
  • Described in this abstract are the results of gene expression analyses from cohorts 1 and 2 of AWARE-1, a collaborative window-of-opportunity study in patients with early-stage breast cancerthat was conducted by Oncolytics Biotech and SOLTI-Innovative Cancer Research.
  • The study combined pelareorep, without or with atezolizumab, and the standard of care therapy according to breast cancer subtype.

Oncolytics Biotech® Announces Presentations at the Upcoming San Antonio Breast Cancer Symposium

Retrieved on: 
Monday, November 21, 2022
SAN, 2021 Essex County Council election, Cancer, TSX, Letrozole, Lymphatic system, PIK3CA, Survival, Neoplasm, Immunotherapy, Paclitaxel, Even and odd functions, Global Vision, EP4, Biotechnology, AB, Safety, Breast cancer, Progression-free survival, Roche, Travel, Phenotype, Research, Patient, COVID-19, ONC, Clinical trial, SD, PD-L1, Diagnosis, Regulation, Biomarker, Pancreatic cancer, Pharmaceutical industry, Medical imaging, Oncolytics Biotech, Pelareorep

(NASDAQ: ONCY) (TSX: ONC) today announced the publication of two abstracts for poster presentations at the upcoming San Antonio Breast Cancer Symposium (SABCS), to be held at the Henry B. Gonzlez Convention Center in San Antonio, Texas from December 6 10, 2022.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today announced the publication of two abstracts for poster presentations at the upcoming San Antonio Breast Cancer Symposium (SABCS), to be held at the Henry B. Gonzlez Convention Center in San Antonio, Texas from December 6 10, 2022.
  • Thebridging trial is designed to accelerate Adlai Nortye's development of pelareorep in China by allowingfuture regulatory submissions to include data from Oncolytics' North American metastatic breast cancer trials, IND-213 and BRACELET-1.
  • Described in this abstract are the results of gene expression analyses from cohorts 1 and 2 of AWARE-1, a collaborative window-of-opportunity study in patients with early-stage breast cancerthat was conducted by Oncolytics Biotech and SOLTI-Innovative Cancer Research.
  • AWARE-1 was an open-label window-of-opportunity study in early-stage breast cancer.The study combined pelareorep, without or with atezolizumab, and the standard of care therapy according to breast cancer subtype.

Treadwell Therapeutics Announces Presentations at the 2022 San Antonio Breast Cancer Symposium Featuring a Clinical Trial Update on the CFI-402257 and CFI-400945 programs

Retrieved on: 
Monday, November 21, 2022
2021 Essex County Council election, TTK, Patient, PLK4, Breast cancer, HPK1, Cancer, Therapy, Treadwell, Science, TCR, Pharmaceutical industry

"We are grateful that several abstracts highlighting our TTK and PLK4 inhibitor programs have been selected for presentation," said Dr. Michael Tusche, Treadwell co-CEO.

Key Points: 
  • "We are grateful that several abstracts highlighting our TTK and PLK4 inhibitor programs have been selected for presentation," said Dr. Michael Tusche, Treadwell co-CEO.
  • "We look forward to additional data from these studies, as we further characterize the utility of our agents in various breast cancer settings."
  • The Company's internally developed clinical pipeline includes CFI-400945, CFI-402257 and CFI-402411 (HPK1 inhibitor).
  • The company is also advancing a pre-clinical pipeline of first-in-class antibody and TCR-based cell therapy assets.

Treadwell Therapeutics Announces Presentations at the 2022 San Antonio Breast Cancer Symposium Featuring a Clinical Trial Update on the CFI-402257 and CFI-400945 programs

Retrieved on: 
Monday, November 21, 2022
2021 Essex County Council election, TTK, Patient, PLK4, Breast cancer, HPK1, Cancer, Therapy, Treadwell, Science, TCR, Pharmaceutical industry

"We are grateful that several abstracts highlighting our TTK and PLK4 inhibitor programs have been selected for presentation," said Dr. Michael Tusche, Treadwell co-CEO.

Key Points: 
  • "We are grateful that several abstracts highlighting our TTK and PLK4 inhibitor programs have been selected for presentation," said Dr. Michael Tusche, Treadwell co-CEO.
  • "We look forward to additional data from these studies, as we further characterize the utility of our agents in various breast cancer settings."
  • The Company's internally developed clinical pipeline includes CFI-400945, CFI-402257 and CFI-402411 (HPK1 inhibitor).
  • The company is also advancing a pre-clinical pipeline of first-in-class antibody and TCR-based cell therapy assets.

WiSE® Technology to Feature in Upcoming APHRS Scientific Session

Retrieved on: 
Thursday, November 17, 2022
2021 Essex County Council election, Hospital, Technology, Silicon, Abstract (summary), EBR, Heart, Wise, James Cook University Hospital, Feasibility, ASX, Bradycardia, Effect, Coronary sinus, Industry, Sale, Company, Longevity, Metal electrode leadless face, Wireless, Patient, Heart failure, CRT, St Thomas' Hospital, Music, Medicine, Medical device

The annual conference is a premier event featuring industry workshops and a core scientific programme delivered by international and regional speakers.

Key Points: 
  • The annual conference is a premier event featuring industry workshops and a core scientific programme delivered by international and regional speakers.
  • Five abstracts featuring WiSE have been accepted for presentations, highlighting the technology's position at the forefront of innovation in the cardiac rhythm management landscape.
  • The abstracts presented at this scientific session strengthen the body of data supporting WiSE while promoting our technology to a wide audience including industry partners and the broader scientific community."
  • EBR Systems' WiSE technology is the world's only wireless, endocardial (inside the heart) pacing system in clinical use for stimulating the heart's left ventricle.

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health to Showcase Novel and Expansive Hematology/Oncology Data at the 64th American Society of Hematology Annual Meeting and Exposition

Retrieved on: 
Tuesday, November 15, 2022
Lymphoma, 2021 Essex County Council election, National Cancer Institute, Cell therapy, Holism, RICE, DLBCL, Rituximab, Hodgkin lymphoma, Exposition, Lymphatic system, MS, NEW, Rutgers Cancer Institute of New Jersey, Safety, Leukemia, Consortium, Society, Degenerative disease, Carboplatin, Ifosfamide, Transplant, Patient, Robert Wood Johnson Medical School, Etoposide, ASH, NCI-designated Cancer Center, Rutgers University, Multiple myeloma, Diagnosis, RWJBarnabas Health, Pharmaceutical industry, Medicine, MD, Polatuzumab vedotin

NEW BRUNSWICK, N.J., Nov. 15, 2022 /PRNewswire/ -- Physician-scientists from Rutgers Cancer Institute of New Jersey and RWJBarnabas Health will present a wide-ranging scope of new hematology/oncology data from their clinical research program at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, being held in New Orleans, Louisiana (and virtually) from December 10-13, 2022. A total of 24 abstracts have been accepted, comprising clinical data and analyses that advance the understanding and treatment of such blood cancers as lymphoma, leukemia and myeloma. Rutgers Cancer Institute, together with RWJBarnabas Health, is New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center and the leading cancer program in the state.

Key Points: 
  • A total of 24 abstracts have been accepted, comprising clinical data and analyses that advance the understanding and treatment of such blood cancers as lymphoma, leukemia and myeloma.
  • Rutgers Cancer Institute, together with RWJBarnabas Health, is New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center and the leading cancer program in the state.
  • Pola is an antibody-drug conjugate that is safe and effective when combined with chemotherapy in frontline and relapsed, transplant-ineligible DLBCL patients.
  • The full list of presentations at this year's ASH Annual Meeting and Exposition follows:

Implantica publishes Interim Report Q3 2022

Retrieved on: 
Tuesday, November 15, 2022
2021 Essex County Council election, Conference, University of York, ICER, GHP, GERD, Awareness, News, Nissen fundoplication, Pharmacoeconomics, EFS, University, Reuters - The World's Most Innovative Universities, Standard of care, PPI, Insurance, Magnetism, Investment, Patient, Hospital, EUR, Gastroesophageal reflux disease, International Society, Pharmaceutical industry

Implantica initiated a therapy awareness project to enhance the patient, physician and caregiver's awareness about gastroesophageal reflux disease (GERD) and anti-reflux surgery.

Key Points: 
  • Implantica initiated a therapy awareness project to enhance the patient, physician and caregiver's awareness about gastroesophageal reflux disease (GERD) and anti-reflux surgery.
  • Implantica receives Global Health & Pharma's Most Innovative MedTech Company Central Europe Award for 2022 based on a serious due diligence by GHP, identifying the high innovation level of Implantica.
  • Implantica attended the European Foregut Society (EFS) Conference in Belgrade, Serbia where the good clinical outcomes of RefluxStop were presented by Dr. med.
  • Implantica will hold a telephone conference on November 15 at 15:00 CET.

Tremeau Pharmaceuticals ACR Convergence 2022 Presentations Highlight Potential Path Forward for Historical VIOXX

Retrieved on: 
Friday, November 11, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, ACR, FDA, Arthritis, Bleeding, Nonsteroidal anti-inflammatory drug, Trémeau, Pain, Tmax, Perception, 2021 Essex County Council election, Degenerative disease, TRM, NSAID, CV, View, Risk, Pain management, Patient, Chronic pain, Gastrointestinal bleeding, American College, Bleeding time, Traffic barrier, Medication, Pharmaceutical industry, Generic drug, Rheumatology, Rofecoxib

Tremeau Pharmaceuticals will present two abstracts highlighting a potential path forward for rofecoxib, the active ingredient in VIOXX, as a non-opioid treatment option during the American College of Rheumatologys (ACR) Convergence Meeting in Philadelphia.

Key Points: 
  • Tremeau Pharmaceuticals will present two abstracts highlighting a potential path forward for rofecoxib, the active ingredient in VIOXX, as a non-opioid treatment option during the American College of Rheumatologys (ACR) Convergence Meeting in Philadelphia.
  • These patients are often left with the inadequate options of living with pain, or resorting to opioids for pain relief.
  • Tremeau is developing TRM-201 (rofecoxib), a COX-2 selective NSAID, as a potential treatment option for people living with pain whose needs are not satisfied by traditional NSAIDs, Dr. Boice added.
  • VIOXX is a registered trademark of Tremeau Pharmaceuticals, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20221111005054/en/

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic Studies for AQST-109 (epinephrine sublingual film) at American Academy of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting

Retrieved on: 
Wednesday, November 9, 2022
ACAAI, GLOBE, Private Securities Litigation Reform Act, 2021 Essex County Council election, Intellectual property, Marketing, Formulation, Sunlight, Weather, American College of Allergy, Asthma and Immunology, Research, Risk, Health, Technology, Tongue, U.S. Securities and Exchange Commission, Sale, Adrenaline, COVID-19, Legislation, Allergy, Therapy, Rain, Annual report, Failure, NASDAQ, Diazepam, Compliance, Safety, Company, Drug development, Anaphylaxis, Patient, Degenerative disease, Growth, Securities & Exchange Commission of Pakistan, Central nervous system, Industry, CNS, FDA, American College, Pharmaceutical industry

As many as 49 million people in the United States are at chronic risk for anaphylaxis.

Key Points: 
  • As many as 49 million people in the United States are at chronic risk for anaphylaxis.
  • Lifetime prevalence is at least 5%, or more than 16 million people in the United States.
  • The frequency of hospital admissions for anaphylaxis has increased 500-700% in the last 10-15 years.
  • Aquestive is developing pharmaceutical products to deliver complex molecules through alternative administrations to invasive and inconvenient standard of care therapies.

DBV Technologies to Highlight New Clinical Data at ACAAI 2022

Retrieved on: 
Wednesday, November 9, 2022
Aurora, ACAAI, 2021 Essex County Council election, Convention, Reaction, Children's Hospital Colorado, Nasdaq, Food, Knowledge, Immunotherapy, EST, Risk, ISIN, Epidemiology, Regulation of tobacco by the U.S. Food and Drug Administration, Allergy, Food allergy, SEC, Safety, U.S. Securities and Exchange Commission, Company, Ticker, Product, European Medicines Agency, MBA, Skin, Peanut allergy, Porta Palazzo Exhibition Hall, Policy by press release, Immune system, Patient, Evolution, Treatment, DBV Technologies, AMF, American College, Pharmaceutical industry, DBV, Euronext, Euronext Paris

DBV will also host a booth in the ACAAI Exhibit Hall from Friday, November 11, through Sunday, November 13.

Key Points: 
  • DBV will also host a booth in the ACAAI Exhibit Hall from Friday, November 11, through Sunday, November 13.
  • DBV is the sole sponsor, via an independent educational grant, of the International Food Allergy Symposium, a full-day symposium that kicks off ACAAI.
  • The additional data being presented at this year's ACAAI meeting highlight the potential for Viaskin Peanut as a treatment option for this young and vulnerable patient population if approved, said Dr. Pharis Mohideen, Chief Medical Officer of DBV Technologies.
  • Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release.